Supplementary Figure 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer

Ítems similars

• Supplementary Tables 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer
  per: Emmanuel F. Petricoin (22436166)
  Publicat: (2025)
• Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
  per: Srivandana Akshintala (16610490)
  Publicat: (2025)
• Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
  per: Srivandana Akshintala (16610490)
  Publicat: (2025)
• Figure 1 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
  per: Monica M. Mita (21585118)
  Publicat: (2025)
• Figure 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
  per: Monica M. Mita (21585118)
  Publicat: (2025)